Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | SI | P14410 | 2/20 | 0.58 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL53913 | 0.89 | — | — | |
| SCHEMBL3441102 | 0.89 | MGAM (0.69) | MGAMGAASIMGAM2TSHR | |
| Hydrochloric Acid SCHEMBL5097295 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL4776595 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL9461843 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL11587161 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL708003 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| Lithium SCHEMBL11306430 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| Bromide SCHEMBL29190335 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL29911291 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12113460-B2 | Electrostatic machine system and method of operation | C-Motive Technologies, Inc. (US) | 2024-10-08 | — | — | US | claimed |
| CN-117700654-A | Copolyester for weather-resistant coating and preparation method and application thereof | 中瀚新材料科技有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-114805647-A | Catalyst composition for olefin polymerization and application thereof | 北京肯佰恩科技发展有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114605622-A | Aliphatic polyester with malonic acid structure and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-111333509-B | Apple flavor compound, preparation method thereof and food additive | 东莞波顿香料有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-20210391810-A1 | ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION | C-Motive Technologies, Inc. (US) | 2021-12-16 | — | — | US | claimed |
| EP-3881425-A1 | ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION | C-Motive Technologies, Inc. (US) | 2021-09-22 | — | — | EP | claimed |
| CN-112574140-A | Preparation method of novel epoxy end-capping agent | 天津工业大学 | 2021-03-30 | — | — | CN | claimed |
| CN-112225657-A | Preparation method of flurbiprofen | 北京泰德制药股份有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-111333509-A | Apple flavor compound, preparation method thereof and food additive | 东莞波顿香料有限公司 | 2020-06-26 | — | — | CN | claimed |
| WO-2020101796-A1 | ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION | C-Motive Technologies, Inc. (US) | 2020-05-22 | — | — | WO | claimed |
| US-20080182767-A1 | Compounds and Lubricating Compositions Containing the Compounds | AFTON CHEMICAL CORPORATION | 2008-07-31 | — | — | US | claimed |
| WO-2001072704-A1 | AZETIDINONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A METHOD FOR PRODUCING 1-β-ALKYL AZETIDINONE USING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2001-10-04 | — | — | WO | claimed |
| EP-0674233-B1 | Recording sheets | XEROX CORP (US) | 2000-05-24 | — | — | EP | claimed |
| US-6025487-A | Isomerisation process | GLAXO WELLCOME SPA (IT) | 2000-02-15 | — | — | US | claimed |
| US-5928765-A | Recording sheets | XEROX CORPORATION (US) | 1999-07-27 | — | — | US | claimed |
| EP-0871635-A1 | ISOMERISATION PROCESS | GLAXO WELLCOME S.p.A. (IT) | 1998-10-21 | — | — | EP | claimed |
| WO-1997006174-A1 | ISOMERISATION PROCESS | GLAXO WELLCOME SPA (IT) | 1997-02-20 | — | — | WO | claimed |
| EP-0674233-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| EP-4038109-B1 | ZIEGLER-NATTA CATALYSTS FOR OLEFIN POLYMERIZATION | BOREALIS GMBH (AT) | 2025-12-03 | — | — | EP | disclosed |
| US-12391778-B2 | Ziegler-natta catalysts for olefin polymerization | BOREALIS AG (AT) | 2025-08-19 | — | — | US | disclosed |
| EP-3730529-B1 | BLOCKED ISOCYANATE | MITSUI CHEMICALS INC (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-118909170-A | Catalyst system for preparing olefin polymer and application thereof | 中国石油化工股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-12113460-B2 | Electrostatic machine system and method of operation | C-Motive Technologies, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| CN-114805647-B | Catalyst composition for olefin polymerization and application thereof | 北京肯佰恩科技发展有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117700654-A | Copolyester for weather-resistant coating and preparation method and application thereof | 中瀚新材料科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117480452-A | Photosensitive colored resin composition, cured product, color filter, display device, and method for producing laminate of organic light-emitting element and external light reflection preventing film | DNP精细化工股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230340184-A1 | WATER-DISPERSIBLE BLOCKED ISOCYANATE, FIBER-TREATING AGENT, WATER REPELLENT, COATING COMPOSITION, AND ADHESIVE | MITSUI CHEMICALS, INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2023190497-A1 | ANTIBACTERIAL AGENT | 三井化学株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-4215592-A1 | WATER-DISPERSIBLE BLOCKED ISOCYANATE, FIBER-TREATING AGENT, WATER REPELLENT, COATING COMPOSITION, AND ADHESIVE | Mitsui Chemicals, Inc. (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-113912755-B | Catalyst composition for olefin polymerization and application thereof | 张一锴 | 2023-06-02 | — | — | CN | disclosed |
| US-20230104741-A1 | Primer Composition for Optical Article, and Laminate | TOKUYAMA CORPORATION (JP) | 2023-04-06 | — | — | US | disclosed |
| CN-115806511-A | Synthesis method of 5-p-toluenesulfonyl pentyl-2-methyl diethyl malonate | 江苏省原子医学研究所 | 2023-03-17 | — | — | CN | disclosed |
| CN-115806511-A | Synthesis method of 5-p-toluenesulfonyl pentyl-2-methyl diethyl malonate | 江苏省原子医学研究所 | 2023-03-17 | — | — | CN | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115666539-A | Treatment of psoriasis and skin inflammatory diseases | 兹杜斯生命科学有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220380496-A1 | ZIEGLER-NATTA CATALYSTS FOR OLEFIN POLYMERIZATION | BOREALIS AG (AT) | 2022-12-01 | — | — | US | disclosed |
| EP-4088927-A1 | PRIMER COMPOSITION FOR OPTICAL ARTICLE, AND LAMINATE | Tokuyama Corporation (JP) | 2022-11-16 | — | — | EP | disclosed |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| EP-4038109-A1 | ZIEGLER-NATTA CATALYSTS FOR OLEFIN POLYMERIZATION | Borealis AG (AT) | 2022-08-10 | — | — | EP | disclosed |
| CN-114805647-A | Catalyst composition for olefin polymerization and application thereof | 北京肯佰恩科技发展有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114605622-A | Aliphatic polyester with malonic acid structure and preparation method and application thereof | 苏州瀚海新材料有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-111333509-B | Apple flavor compound, preparation method thereof and food additive | 东莞波顿香料有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022107418-A1 | COATING MATERIAL COMPOSITION | 関西ペイント株式会社 | 2022-05-27 | — | — | WO | disclosed |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2022-04-28 | — | — | US | disclosed |
| CN-113912755-A | Catalyst composition for olefin polymerization and application thereof | 张一锴 | 2022-01-11 | — | — | CN | disclosed |
| US-20210391810-A1 | ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION | C-Motive Technologies, Inc. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3881425-A1 | ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION | C-Motive Technologies, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-113273075-A | Electrostatic machine system and method of operation | C-莫蒂夫技术公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-109694420-B | Catalyst system for olefin polymerization, prepolymerized catalyst and olefin polymerization process | 中国石油化工股份有限公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11021617-B2 | Polymers including one or more 1,1-disubstituted alkene compounds and polymer compositions thereof | SIRRUS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2021064078-A1 | ZIEGLER-NATTA CATALYSTS FOR OLEFIN POLYMERIZATION | BOREALIS AG (AT) | 2021-04-08 | — | — | WO | disclosed |
| CN-112574140-A | Preparation method of novel epoxy end-capping agent | 天津工业大学 | 2021-03-30 | — | — | CN | disclosed |
| EP-3786199-A1 | POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS AND POLYMER COMPOSITIONS THEREOF | Sirrus, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112225657-A | Preparation method of flurbiprofen | 北京泰德制药股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-3191533-B1 | POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS AND POLYMER COMPOSITIONS THEREOF | SIRRUS INC (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-107802623-B | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | 开曼化学股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3730529-A1 | BLOCKED ISOCYANATE | Mitsui Chemicals, Inc. (JP) | 2020-10-28 | — | — | EP | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106748951-B | Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions | 开曼化学股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3683267-A1 | EMULSION POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS, EMULSION METHODS, AND POLYMER COMPOSITIONS | Sirrus, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3191546-B1 | EMULSION POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS, EMULSION METHODS, AND POLYMER COMPOSITIONS | SIRRUS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2020-07-02 | — | — | US | disclosed |
| CN-111333509-A | Apple flavor compound, preparation method thereof and food additive | 东莞波顿香料有限公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3176162-B1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2020101796-A1 | ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION | C-Motive Technologies, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| EP-3642204-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10633566-B2 | Polymers containing a 1,1-disubstituted alkene compound | SIRRUS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| CN-111018704-A | Preparation method of diethyl methylmalonate by taking heteropoly acid as catalyst | 江西万里药业有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-2117909-B2 | REINFORCING SYSTEM FOR REINFORCING A CAVITY OF A STRUCTURAL ELEMENT | SIKA TECH AG (CH) | 2020-04-01 | — | — | EP | disclosed |
| US-10556862-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190263955-A1 | POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS AND POLYMER COMPOSITIONS THEREOF | SIRRUS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190202816-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2019-07-04 | — | — | US | disclosed |
| US-10308802-B2 | Polymers including one or more 1,1-disubstituted alkene compounds and polymer compositions thereof | SIRRUS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190153272-A1 | POLYMERS CONTAINING A 1,1-DISUBSTITUTED ALKENE COMPOUND | SIRRUS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190144435-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | MYOMETRICS, LLC (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2019-03-28 | — | — | US | disclosed |
| US-10184073-B2 | Emulsion including polymers containing a 1,1-disubstituted alkene compound, adhesives, coatings, and methods thereof | SIRRUS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| WO-2018234345-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| EP-3235817-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-3394066-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2018-10-18 | — | — | US | disclosed |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10081685-B2 | Emulson polymers including one or more 1,1-disubstituted alkene compounds, emulson methods, and polymer compositions | SIRRUS, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9914725-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| EP-2669270-B1 | INDOLE-RELATED COMPOUNDS AS URAT1 INHIBITORS | SATO PHARMA (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9803130-B2 | Methods of activating enzyme breakers | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3235817-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170275446-A1 | POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS AND POLYMER COMPOSITIONS THEREOF | NIPPON SHOKUBAI CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20170260173-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS | MYOMETRICS, LLC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3191546-A1 | EMULSION POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS, EMULSION METHODS, AND POLYMER COMPOSITIONS | Sirrus, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3191533-A1 | POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS AND POLYMER COMPOSITIONS THEREOF | Sirrus, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170198181-A1 | EMULSION INCLUDING POLYMERS CONTAINING A 1,1-DISUBSTITUTED ALKENE COMPOUND, ADHESIVES, COATINGS, AND METHODS THEREOF | NIPPON SHOKUBAI CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9701630-B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170190807-A1 | EMULSION POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS, EMULSION METHODS, AND POLYMER COMPOSITIONS | SIRRUS, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9676712-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-3176162-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3175852-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2989098-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9637564-B2 | Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions | SIRRUS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170066751-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160340306-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2016-11-24 | — | — | US | disclosed |
| US-9487478-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2874620-B1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2875022-B1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9440919-B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160158413-A1 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| EP-3021879-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | Cayman Chemical Company, Incorporated (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-3012258-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AND -TRIAZINES AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160096907-A1 | EMULSION POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS, EMULSION METHODS, AND POLYMER COMPOSITIONS | SIRRUS, INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2016040261-A1 | POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS AND POLYMER COMPOSITIONS THEREOF | SIRRUS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040012-A1 | EMULSION POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS, EMULSION METHODS, AND POLYMER COMPOSITIONS | SIRRUS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160060216-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2016-03-03 | — | — | US | disclosed |
| US-20160060253-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL COMPANY, INC. | 2016-03-03 | — | — | US | disclosed |
| EP-2585467-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AND -TRIAZINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2989098-A2 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160031811-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2016-02-04 | — | — | US | disclosed |
| US-9249265-B1 | Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions | SIRRUS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20160024006-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2016-01-28 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970234-A2 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | Cayman Chemical Company, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9238039-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-9180116-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| WO-2015114092-A1 | ANTIFOULING COMPOSITION | JOTUN A/S (NO) | 2015-08-06 | — | — | WO | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-06-25 | — | — | US | disclosed |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2015-06-25 | — | — | US | disclosed |
| EP-2875022-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2874620-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014144584-A2 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144500-A2 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8809330-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8765766-B2 | Pyrimidine derivatives which are antagonists of the vitronectin receptor | GALAPAGOS NV (BE) | 2014-07-01 | — | — | US | disclosed |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-06-05 | — | — | US | disclosed |
| EP-1788049-B1 | THERMOSETTING AQUEOUS COATING COMPOSITION | KANSAI PAINT CO LTD (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-20140121136-A1 | METHODS OF ACTIVATING ENZYME BREAKERS | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2014066708-A1 | METHODS OF ACTIVATING ENZYME BREAKERS | SCHLUMBERGER CANADA LIMITED (CA) | 2014-05-01 | — | — | WO | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2014015247-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015246-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20140005221-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| EP-2669270-A1 | RING-FUSED COMPOUND | Sato Pharmaceutical Co., Ltd. (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-2638034-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2585467-A1 | PYRAZOLO [1, 5 -A]PYRIMIDINES AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2545037-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8216490-B2 | Aqueous primer composition and a process for the application of the same | KANSAI PAINT CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| WO-2012062462-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2012-05-10 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8133896-B2 | Pyrimidine derivatives which are antagonist of the vitronectin receptor | GALAPAGOS NV (BE) | 2012-03-13 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-1268976-B1 | VISCOSITY REDUCTION OF VISCOELASTIC SURFACTANT BASED FLUIDS | SOFITECH NV (BE) | 2011-10-05 | — | — | EP | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110612-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
| EP-1901731-B1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2011-02-17 | — | — | US | disclosed |
| US-7846932-B2 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | GALAPAGOS SAS (FR) | 2010-12-07 | — | — | US | disclosed |
| US-7838076-B2 | Thermosetting aqueous paint composition | KANSAI PAINT CO., LTD. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7825119-B2 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | GALAPAGOS SAS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100041675-A1 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | GALAPAGOS SAS | 2010-02-18 | — | — | US | disclosed |
| EP-1534926-B1 | VISCOSITY REDUCTION OF VISCOELASTIC SURFACTANT BASED FLUIDS | SCHLUMBERGER SERVICES PETROL (FR) | 2009-11-04 | — | — | EP | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| US-20090130322-A1 | Aqueous Primer Composition and a Process for the Application of the Same | KANSAI PAINT CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080182767-A1 | Compounds and Lubricating Compositions Containing the Compounds | AFTON CHEMICAL CORPORATION | 2008-07-31 | — | — | US | disclosed |
| EP-1947153-A1 | AQUEOUS PRIMER COMPOSITION AND METHOD FOR APPLYING SAME | KANSAI PAINT CO., LTD. (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20080095944-A1 | Thermosetting Aqueous Paint Composition | KANSAI PAINT CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1901731-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | PROSKELIA SAS | 2008-03-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070259123-A1 | Aqueous Primer Composition | KANSAI PAINT CO., LTD. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20070237903-A1 | Thermosetting Water-Based Coating Composition and Method of Forming Coating Film | KANSAI PAINT CO., LTD (JP) | 2007-10-11 | — | — | US | disclosed |
| EP-1824812-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1788049-A1 | THERMOSETTING AQUEOUS COATING COMPOSITION | Kansai Paint Co., Ltd. (JP) | 2007-05-23 | — | — | EP | disclosed |
| EP-1780249-A1 | WATER-BASED PRIMER COMPOSITION | KANSAI PAINT CO., LTD. (JP) | 2007-05-02 | — | — | EP | disclosed |
| EP-1770135-A1 | THERMOSETTING WATER-BASED COATING COMPOSITION AND METHOD OF FORMING COATING FILM | Kansai Paint Co., Ltd. (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO., INC. | 2006-12-28 | — | — | US | disclosed |
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-7094773-B2 | LTA4 hydrolase inhibitors | Institut National de la Santa et de la rescherche Medicale Bioprojet (FR) | 2006-08-22 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006057922-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060052398-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS NV (BE) | 2006-03-09 | — | — | US | disclosed |
| CN-1678814-A | Viscosity reduction of viscoelastic surfactant based fluids | SCHLUMBERGER TECHNOLOGY BV (NL) | 2005-10-05 | — | — | CN | disclosed |
| US-6908888-B2 | Viscosity reduction of viscoelastic surfactant based fluids | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1534926-A1 | VISCOSITY REDUCTION OF VISCOELASTIC SURFACTANT BASED FLUIDS | SERVICES PETROLIERS SCHLUMBERGER (FR) | 2005-06-01 | — | — | EP | disclosed |
| US-6881709-B2 | Viscosity reduction of viscoelastic surfactant based fluids | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
| US-6878723-B1 | Carbocyclic and/or heterocyclic amino carboxylic acids, e.g., 2-aminomethyl-6-(p-benzylphenoxy)hexanoic acid; leukotriene A4 hydrolase; treating arthritis and psoriasis; hematoprotective and antimitotic agents | INSTITUT NATIONAL DE LA SANTE ET DE LA RESCHERCHE MEDICALE (INSERM) (FR) | 2005-04-12 | — | — | US | disclosed |
| US-20050027013-A1 | LTA4 hydrolase inhibitors | DANVY DENIS (FR) | 2005-02-03 | — | — | US | disclosed |
| EP-1026198-B1 | Polypropylene resin composition and injection-molded article thereof | MITSUI CHEMICALS INC (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-6759475-B2 | MECHANICAL PROPERTIES AND IN THE FLOWABILITY UPON INJECTION MOLDING AND CAN SERVE FOR A MATERIAL FOR EXHIBITING BETTER APPEARANCE | MITSUI CHEMICALS, INC. (JP) | 2004-07-06 | — | — | US | disclosed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| EP-0916701-B1 | CRYSTALLINE POLYPROPYLENE RESIN COMPOSITION | MITSUI CHEMICALS INC (JP) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004007904-A1 | VISCOSITY REDUCTION OF VISCOELASTIC SURFACTANT BASED FLUIDS | SCHLUMBERGER CANADA LIMITED (CA) | 2004-01-22 | — | — | WO | disclosed |
| EP-0919572-B1 | POLYPROPYLENE RESIN COMPOSITION AND INJECTION-MOLDED ARTICLE | MITSUI CHEMICALS INC (JP) | 2003-12-10 | — | — | EP | disclosed |
| CN-1427919-A | Viscocity reduction of viscoelastic surfactant based fluids | SOFITECH NV (BE) | 2003-07-02 | — | — | CN | disclosed |
| EP-1268976-A2 | VISCOSITY REDUCTION OF VISCOELASTIC SURFACTANT BASED FLUIDS | Sofitech N.V. (BE) | 2003-01-02 | — | — | EP | disclosed |
| US-20020193257-A1 | Viscosity reduction of viscoelastic surfactant based fluids | SCHLUMBERGER TECHNOLOGY CORPORATION | 2002-12-19 | — | — | US | disclosed |
| EP-1105359-B1 | SOLID PHASE SYNTHESIS OF COMPOUNDS BY CARBON-CARBON BOND FORMING MITSUNOBU REACTIONS | PE CORP NY (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020058741-A1 | Resin composition based on crystalline polypropylene | MITSUI CHEMICALS, INC. (JP) | 2002-05-16 | — | — | US | disclosed |
| US-20020004464-A1 | Viscosity reduction of viscoelastic surfactant based fluids | SCHLUMBERGER TECHNOLOGY CORPORATION | 2002-01-10 | — | — | US | disclosed |
| US-6320009-B1 | LIGHT WEIGHT, VERY HIGH VALUES OF STIFFNESS AND HEAT RESISTANCE, SUPERIOR SCRATCHPROONESS, SUPERIOR IN MELT PROCESSIBILITY; INJECTION MOLDINGS | GRAND POLYMER CO LTD (JP) | 2001-11-20 | — | — | US | disclosed |
| WO-2001077487-A2 | VISCOSITY REDUCTION OF VISCOELASTIC SURFACTANT BASED FLUIDS | SOFITECH N.V. (BE) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001072704-A1 | AZETIDINONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A METHOD FOR PRODUCING 1-β-ALKYL AZETIDINONE USING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2001-10-04 | — | — | WO | disclosed |
| EP-1105359-A1 | SOLID PHASE SYNTHESIS OF COMPOUNDS BY CARBON-CARBON BOND FORMING MITSUNOBU REACTIONS | PE Corporation (NY) (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6121055-A | DETECTING COMPOUND IN SAMPLE; MIXING SAMPLE AND CHEMICAL INTERMEDIATE, SEPARATING INSOLUBLE COMPONENT OF MIXTURE, ADDING BINDING COMPONENT AND LABEL TO MIX, SEPARATE BINDING COMPONENT AND LABEL, DETECT BOUND LABEL AND BINDING COMPONENT | ROCHE DIAGNOSTICS CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| EP-1026198-A1 | Polypropylene resin composition and injection-molded article thereof | Grand Polymer Co., Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
| EP-0674233-B1 | Recording sheets | XEROX CORP (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000010942-A1 | SOLID PHASE SYNTHESIS OF COMPOUNDS BY CARBON-CARBON BOND FORMING MITSUNOBU REACTIONS | THE PERKIN-ELMER CORPORATION (US) | 2000-03-02 | — | — | WO | disclosed |
| US-6025487-A | Isomerisation process | GLAXO WELLCOME SPA (IT) | 2000-02-15 | — | — | US | disclosed |
| US-5928765-A | Recording sheets | XEROX CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0919572-A1 | POLYPROPYLENE RESIN COMPOSITION AND INJECTION-MOLDED ARTICLE | Grand Polymer Co., Ltd. (JP) | 1999-06-02 | — | — | EP | disclosed |
| EP-0916701-A1 | CRYSTALLINE POLYPROPYLENE RESIN COMPOSITION | Grand Polymer Co., Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0903382-A1 | Semi-solid hot melt ink compositions containing esters | XEROX CORPORATION (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5876492-A | Ink compositions containing esters | XEROX CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0871635-A1 | ISOMERISATION PROCESS | GLAXO WELLCOME S.p.A. (IT) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997006174-A1 | ISOMERISATION PROCESS | GLAXO WELLCOME SPA (IT) | 1997-02-20 | — | — | WO | disclosed |
| EP-0674233-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| US-5451458-A | Electrography | XEROX CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| US-5449680-A | Antiallergens, antiinflammatory agents; platelet activating factor antagonists | SCHERING CORPORATION (US) | 1995-09-12 | — | — | US | disclosed |
| US-5320775-A | Malonate esters | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1994-06-14 | — | — | US | disclosed |
| EP-0216423-B1 | PESTICIDAL BENZOYLUREA COMPOUNDS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1993-05-12 | — | — | EP | disclosed |
| US-5185334-A | 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use | SCHERING CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0517482-A2 | Bleach precursors | UNILEVER PLC (GB) | 1992-12-09 | — | — | EP | disclosed |
| US-5073341-A | Immunology, diagnosis | BIOTOPE, INC. (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0398990-A1 | 2,2-DISUBSTITUTED GLYCEROL AND GLYCEROL-LIKE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1990-11-28 | — | — | EP | disclosed |
| EP-0206810-B1 | ACRYLATE COMPOUND AND COMPOSITION CONTAINING THE SAME | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1990-04-04 | — | — | EP | disclosed |
| EP-0344276-A1 | METHODS AND DEVICES FOR CONDUCTING ASSAYS | BOEHRINGER MANNHEIM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4873327-A | Pesticidal benzoylurea compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-10 | — | — | US | disclosed |
| US-4868130-A | DENSITY SEPARATION | BIOTOPE, INC. (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0327962-A1 | 2,2-Disubstituted glycerol and glycerol-like compounds, compositions and methods of use | SCHERING CORPORATION (US) | 1989-08-16 | — | — | EP | disclosed |
| WO-1989007099-A1 | 2,2-DISUBSTITUTED GLYCEROL AND GLYCEROL-LIKE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1989-08-10 | — | — | WO | disclosed |
| WO-1989007100-A1 | 2,2-DISUBSTITUTED GLYCEROL AND GLYCEROL-LIKE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1989-08-10 | — | — | WO | disclosed |
| US-4849401-A | Alcohols containing 2-methylphenyl or 2-methoxyphenyl groups, and fragrances containing same | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE, GMBH (DE) | 1989-07-18 | — | — | US | disclosed |
| US-4755620-A | Acrylate compound and composition containing the same | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1988-07-05 | — | — | US | disclosed |
| US-4745113-A | MITICIDES, INSECTICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-05-17 | — | — | US | disclosed |
| EP-0216423-A2 | Pesticidal benzoylurea compounds | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-04-01 | — | — | EP | disclosed |
| EP-0210025-A2 | 5-Substituted-6-aminopyrimidine derivatives, composition and uses | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-01-28 | — | — | EP | disclosed |
| EP-0206810-A2 | Acrylate compound and composition containing the same | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4617393-A | CONGESITIVE HEART FAILURE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-10-14 | — | — | US | disclosed |
| EP-0008446-B1 | PROCESS FOR THE PREPARATION OF CARBAZOLES AND NOVEL CARBAZOLE DERIVATIVES UTILIZED THEREIN | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-09-22 | — | — | EP | disclosed |
| US-4299926-A | STERICALLY HINDERED POLYALKYLPIPERIDINE | CIBA-GEIGY CORPORATION (US) | 1981-11-10 | — | — | US | disclosed |
| US-4282156-A | Method for the production of novel anhydride polycarboxylates | LEVER BROTHERS COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| US-4272442-A | Certain tricarboxylic acid derivatives | LEVER BROTHERS COMPANY (US) | 1981-06-09 | — | — | US | disclosed |
| US-4260689-A | PIPERIDONE-CONTAINING POLYAMINES | CIBA-GEIGY CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
| US-4260691-A | POLYURETHANES WITH PIPERIDINE-CONTAINING MONOMERS | CIBA-GEIGY CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
| US-4250268-A | Polysilylesters having a polyalkylpiperidine as part of the polymer useful as light stabilizers for plastics | CIBA-GEIGY CORPORATION (US) | 1981-02-10 | — | — | US | disclosed |
| US-4236027-A | Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same | AMERICAN CYANAMID COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4234700-A | POLYCARBONATE OR POLYUREA CONTAINING POLYALKYLPIPERIDINE GROUPS | CIBA-GEIGY CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
| US-4234699-A | POLYETHERS CONTAINING POLYALKYLPIPERIDINE GROUPS | CIBA-GEIGY CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
| US-4233410-A | STERICALLY HINDERED POLYUREAS OF LOW MOLECULAR WEIGHT | CIBA-GEIGY CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| US-4233412-A | POLYESTERS CONTAINING STERICALLY HINDERED ALKYLPIPERIDINE GROUPS | CIBA-GEIGY CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| US-4232131-A | POLYAMIDE | CIBA-GEIGY CORPORATION (US) | 1980-11-04 | — | — | US | disclosed |
| US-4226781-A | 1,1,2,3-Propane tetracarboxylic acid compounds | LEVER BROTHERS COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-4226774-A | Carbazole melonates | HOFFMANN-LA ROCHE INC. (US) | 1980-10-07 | — | — | US | disclosed |
| US-4193923-A | Tetrahydro 2-carbazolyl methyl malonate derivatives | HOFFMANN-LA ROCHE INC. (US) | 1980-03-18 | — | — | US | disclosed |
| EP-0008446-A1 | Process for the preparation of carbazoles and novel carbazole derivatives utilized therein | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-03-05 | — | — | EP | disclosed |
| US-4182805-A | Decyanation | POLAROID CORPORATION (US) | 1980-01-08 | — | — | US | disclosed |
| US-4158007-A | Carbazole methyl malonates | HOFFMANN-LA ROCHE INC. (US) | 1979-06-12 | — | — | US | disclosed |
| US-4152524-A | BRONCHODILATORS, HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4146543-A | Reaction of maleic anhydride with active methylene or methine containing compounds | LEVER BROTHERS COMPANY (US) | 1979-03-27 | — | — | US | disclosed |
| US-4134894-A | Pyrrolo[1,2-a]indole compounds | WARNER-LAMBERT COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4110424-A | PROCESS FOR THE PRODUCTION OF CYANIC ACID AND CARBOXAMIDES | POLAROID CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4076947-A | BRONCHODILATORS, HYPOTENSIVE AGENTS, ANTIULCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-3997682-A | Oleaginous food flavored with certain alpha carboxy acids and/or esters thereof | ANDERSON, CLAYTON & CO. (US) | 1976-12-14 | — | — | US | disclosed |
| US-3997682-A | Oleaginous food flavored with certain alpha carboxy acids and/or esters thereof | ANDERSON, CLAYTON & CO. (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052398-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | MGAM 3114/4885GAA 3727/4885SI 2055/4885 |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MGAM 4137/4885GAA 1676/4885SI 1262/4885 |
| US-20100041675-A1 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | TBXA2R, GPR55, ADGRE5 | MGAM 4835/4885GAA 4482/4885SI 3531/4885 |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | HCAR1, HCAR2, FFAR1 | MGAM 2937/4885GAA 1439/4885SI 1871/4885 |
| US-20190263955-A1 | POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS AND POLYMER COMPOSITIONS THEREOF | PCBP1, PARG, PARP1 | MGAM 877/4885GAA 1306/4885SI 4175/4885 |
| US-10308802-B2 | Polymers including one or more 1,1-disubstituted alkene compounds and polymer compositions thereof | PCBP1, PARG, PARP1 | MGAM 822/4885GAA 1196/4885SI 4041/4885 |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MGAM 4137/4885GAA 1676/4885SI 1262/4885 |
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | MGAM 4699/4885GAA 4196/4885SI 4411/4885 |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | MGAM 3335/4885GAA 1543/4885SI 4321/4885 |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | MGAM 4558/4885GAA 4439/4885SI 3429/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | MGAM 3029/4885GAA 1257/4885SI 1714/4885 |
| US-10556862-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | MGAM 3832/4885GAA 3327/4885SI 4835/4885 |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | MGAM 3114/4885GAA 3727/4885SI 2055/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | MGAM 3335/4885GAA 1543/4885SI 4321/4885 |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MGAM 1447/4885GAA 2587/4885SI 3848/4885 |
| US-20170275446-A1 | POLYMERS INCLUDING ONE OR MORE 1,1-DISUBSTITUTED ALKENE COMPOUNDS AND POLYMER COMPOSITIONS THEREOF | PCBP1, PARG, PARP1 | MGAM 822/4885GAA 1196/4885SI 4041/4885 |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MGAM 3832/4885GAA 3327/4885SI 4835/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | MGAM 3832/4885GAA 3327/4885SI 4835/4885 |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MGAM 3832/4885GAA 3327/4885SI 4835/4885 |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | JUN, CHUK, RELA | MGAM 3656/4885GAA 4069/4885SI 1299/4885 |
| US-12391778-B2 | Ziegler-natta catalysts for olefin polymerization | PNMT, INMT, NAT1 | MGAM 1236/4885GAA 1532/4885SI 3090/4885 |
| US-20160031811-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MGAM 3532/4885GAA 3038/4885SI 4504/4885 |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MGAM 1660/4885GAA 4011/4885SI 3309/4885 |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MGAM 4137/4885GAA 1676/4885SI 1262/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MGAM 4137/4885GAA 1676/4885SI 1262/4885 |
| US-20170260173-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS | PTGER4, PTGER1, EPB41 | MGAM 2351/4885GAA 2090/4885SI 4294/4885 |
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MGAM 3832/4885GAA 3327/4885SI 4835/4885 |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MGAM 4137/4885GAA 1676/4885SI 1262/4885 |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MGAM 4137/4885GAA 1676/4885SI 1262/4885 |
| US-20050027013-A1 | LTA4 hydrolase inhibitors | LTA4H, LTC4S, LTB4R | MGAM 1368/4885GAA 611/4885SI 1544/4885 |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | MGAM 2965/4885GAA 1437/4885SI 1660/4885 |
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, OPRM1, OPRK1 | MGAM 4583/4885GAA 2797/4885SI 1966/4885 |
| US-20190202816-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | MGAM 3290/4885GAA 2967/4885SI 4212/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | MGAM 3832/4885GAA 3327/4885SI 4835/4885 |
| US-20160024006-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MGAM 3832/4885GAA 3327/4885SI 4835/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | MGAM 3335/4885GAA 1543/4885SI 4321/4885 |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | PTGER4, PTGER1, PTGIR | MGAM 3290/4885GAA 2967/4885SI 4212/4885 |
| US-20160340306-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MGAM 1751/4885GAA 2212/4885SI 4420/4885 |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | MGAM 4459/4885GAA 4383/4885SI 3309/4885 |
| US-10633566-B2 | Polymers containing a 1,1-disubstituted alkene compound | ALG8, PCNA, PARP1 | MGAM 236/4885GAA 955/4885SI 2921/4885 |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | CALCR, PTH1R, CALCRL | MGAM 4852/4885GAA 4405/4885SI 3503/4885 |
| US-11021617-B2 | Polymers including one or more 1,1-disubstituted alkene compounds and polymer compositions thereof | PCBP1, PARG, PARP1 | MGAM 877/4885GAA 1306/4885SI 4175/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MGAM 1447/4885GAA 2587/4885SI 3848/4885 |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | MGAM 4665/4885GAA 4404/4885SI 4542/4885 |
| US-20150203490-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | MGAM 4500/4885GAA 2071/4885SI 4695/4885 |
| US-20180170918-A1 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | MGAM 3290/4885GAA 2967/4885SI 4212/4885 |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | MGAM 4706/4885GAA 4340/4885SI 4512/4885 |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | MGAM 4699/4885GAA 4196/4885SI 4411/4885 |
| US-20190144435-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MGAM 1751/4885GAA 2212/4885SI 4420/4885 |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MGAM 4137/4885GAA 1676/4885SI 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.